Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Howell

Showing results (291-300 of 339) with videos related to

Pageof 34
Sort By:
Cancers|December 15, 2020
Long-Term Evaluation of Women Referred to a Breast Cancer Family History Clinic (Manchester UK 1987-2020)Anthony Howell, Ashu Gandhi, Sacha Howell, et al.
Breast Cancer Research and Treatment|April 2, 2014
MRI breast screening in high-risk women: cancer detection and survival analysisD Gareth Evans, Evans D Gareth, Nisha Kesavan, et al.
Breast Cancer Research : BCR|December 3, 2015
Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohortAdam R Brentnall, Elaine F Harkness, Susan M Astley, et al.
The Lancet. Oncology|August 2, 2013
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trialStephen Rd Johnston, Lucy S Kilburn, Paul Ellis, et al.
Journal of Medical Genetics|March 24, 2021
High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancerD Gareth Evans, Elke Maria van Veen, Helen J Byers, et al.
Genetics in Medicine Open|December 13, 2024
Population-based germline testing of <i>BRCA1, BRCA2</i>, and <i>PALB2</i> in breast cancer patients in the United Kingdom: Evidence to support extended testing, and definition of groups who may not require testingD Gareth Evans, Emma R Woodward, George J Burghel, et al.
Annals of Internal Medicine|January 17, 2018
White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer RiskPer E Lønning, Elisabet O Berge, Merete Bjørnslett, et al.
Cell Reports|September 22, 2015
Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell ActivityBruno M Simões, Ciara S O'Brien, Rachel Eyre, et al.
BMC Cancer|June 20, 2020
What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420)David P French, Susan Astley, Adam R Brentnall, et al.
British Journal of Cancer|April 24, 2023
Correction To: Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420)D Gareth Evans, Lorna McWilliams, Susan Astley, et al.
Pageof 34

Showing results (291-300 of 339) with videos related to

Sort By:
Pageof 34
Cancers|December 15, 2020
Long-Term Evaluation of Women Referred to a Breast Cancer Family History Clinic (Manchester UK 1987-2020)Anthony Howell, Ashu Gandhi, Sacha Howell, et al.
Breast Cancer Research and Treatment|April 2, 2014
MRI breast screening in high-risk women: cancer detection and survival analysisD Gareth Evans, Evans D Gareth, Nisha Kesavan, et al.
Breast Cancer Research : BCR|December 3, 2015
Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohortAdam R Brentnall, Elaine F Harkness, Susan M Astley, et al.
The Lancet. Oncology|August 2, 2013
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trialStephen Rd Johnston, Lucy S Kilburn, Paul Ellis, et al.
Journal of Medical Genetics|March 24, 2021
High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancerD Gareth Evans, Elke Maria van Veen, Helen J Byers, et al.
Genetics in Medicine Open|December 13, 2024
Population-based germline testing of <i>BRCA1, BRCA2</i>, and <i>PALB2</i> in breast cancer patients in the United Kingdom: Evidence to support extended testing, and definition of groups who may not require testingD Gareth Evans, Emma R Woodward, George J Burghel, et al.
Annals of Internal Medicine|January 17, 2018
White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer RiskPer E Lønning, Elisabet O Berge, Merete Bjørnslett, et al.
Cell Reports|September 22, 2015
Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell ActivityBruno M Simões, Ciara S O'Brien, Rachel Eyre, et al.
BMC Cancer|June 20, 2020
What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420)David P French, Susan Astley, Adam R Brentnall, et al.
British Journal of Cancer|April 24, 2023
Correction To: Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420)D Gareth Evans, Lorna McWilliams, Susan Astley, et al.
Pageof 34